In Vivo and In Vitro Approaches to Validate the Effectiveness of QMatrix, as a new reconstructive and regenerative biomaterial in dentistry

• Grant number: 25/01402-2
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: July 01, 2025
• End date: June 30, 2027
• Field of knowledge: Health Sciences - Dentistry - Endodontics
• Principal Investigator: Claudia Larissa Viana da Silva
• Grantee: Claudia Larissa Viana da Silva
• Associated researchers: Karina Fittipaldi Bombonato Prado
• Associated research grant: 23/05736-7 - Preclinical validation of reconstructive/regenerative biomaterial for dentistry, AP.PIPE

Abstract

The PIPE Phase II project seeks to validate the QMatrix biomaterial in the regeneration of dental and bone tissues, exploring in vitro and in vivo approaches. Tissue regeneration in dentistry faces challenges such as the limited regeneration capacity of dental pulp and the lack of suitable biomaterials. QMatrix, innovative because it is bioidentical to human collagen and free of animal components, promises to overcome these limitations with greater biocompatibility and regenerative efficacy.The project involves three main stages: (1) in vitro tests with monolayer cells to evaluate mineralization and enzymatic activity; (2) tests with three-dimensional models (spheroids) for more realistic analyses of possibilities and gene expression; and (3) in vivo tests in Wistar rats to confirm tissue regeneration and interaction with dental cells. In Phase I, QMatrix showed high biocompatibility and the ability to induce odontogenesis, but advances are needed to validate its effects in more complex contexts. Quantis has a unique technological approach, based on 3D bioprinting and sustainable methods. The QMatrix production process has already been patented, standing out for its innovation and market potential. The development of this project not only seeks to introduce a minimally invasive approach in dental practice, but also represents a significant opportunity for technological advancement in the sector, significantly improving treatment paradigms in tissue and bone regeneration. (AU)